ARH 050642
Latest Information Update: 11 Dec 2001
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atrial fibrillation
Most Recent Events
- 11 Dec 2001 Discontinued-Preclinical for Atrial fibrillation in Europe (Unknown route)
- 11 Dec 2001 Discontinued-Preclinical for Atrial fibrillation in USA (Unknown route)
- 15 Feb 2000 New profile